Likewise, the authors showed that miR-526b-3p mediates anti-tumor effects and that its inhibition was neutralized with Avelumab treatment, indicating that PD-L1 is a downstream target of miR-526b-3p/STAT3 in lung cancer. This evidence concerns the gene STAT3 and lung carcinoma.